Results 201 to 210 of about 207,009 (370)

When worlds collide: Th17 and Treg cells in cancer and autoimmunity

open access: yesCellular & Molecular Immunology, 2018
H. Knochelmann   +6 more
semanticscholar   +1 more source

YC‐4‐3, a Novel Glycogen Synthase Kinase 3β Inhibitor, Alleviates the Endoplasmic Reticulum Stress of Macrophages in Primary Immune Thrombocytopenia

open access: yesAdvanced Science, EarlyView.
A patented GSK‐3β inhibitor (GSK‐3βi), new benzothiazepinone compounds (BTZs), YC‐4‐3, can modulate the inflammatory status of macrophages in primary immune thrombocytopenia (ITP), and improve the thrombocytopenia in murine ITP models by directly interacting with endoplasmic reticulum (ER) stress response.
Pengcheng Xu   +10 more
wiley   +1 more source

Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia

open access: yesAmerican Journal of Hematology, Volume 98, Issue 1, Page 122-130, January 2023., 2023
Abstract Major options for second‐line therapy in adults with chronic immune thrombocytopenia (ITP) include splenectomy, rituximab, and thrombopoietin receptor agonists (TRAs). The American Society of Hematology guidelines recommend rituximab over splenectomy, TRAs over rituximab, and splenectomy or TRAs while noting a lack of evidence on the cost ...
George Goshua   +5 more
wiley   +1 more source

Histone Deacetylase 6 (HDAC6) in Ciliopathies: Emerging Insights and Therapeutic Implications

open access: yesAdvanced Science, EarlyView.
HDAC6 regulates primary cilia, crucial for cellular signalling and environmental responses. Dysregulation of HDAC6 contributes to ciliopathies, affecting multiple organs. This review examines HDAC6's role in ciliogenesis, its interaction with signaling molecules, and its potential as a therapeutic target.
Zhiyi Wang   +5 more
wiley   +1 more source

Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV‐2 variants, but preserved antigen‐specific T cell responses

open access: yesAmerican Journal of Hematology, Volume 98, Issue 1, Page 131-139, January 2023., 2023
Abstract Patients with indolent lymphoma undertaking recurrent or continuous B cell suppression are at risk of severe COVID‐19. Patients and healthy controls (HC; N = 13) received two doses of BNT162b2: follicular lymphoma (FL; N = 35) who were treatment naïve (TN; N = 11) or received immunochemotherapy (ICT; N = 23) and Waldenström's macroglobulinemia
Brendan Beaton   +20 more
wiley   +1 more source

Editorial: Women in thyroid endocrinology 2022. [PDF]

open access: yesFront Endocrinol (Lausanne)
Ward LS, Ugolini C, Elisei R.
europepmc   +1 more source

Diabetes Mellitus and Thyroid Autoimmunity in Gonadal Dysgenesis

open access: bronze, 1973
J. Van Campenhout, A. Antaki, E Rasio
openalex   +1 more source

Home - About - Disclaimer - Privacy